and 0.2 ml of saline). The following substances were administered intragastrically 2 times a day at 7-hour intervals for 30 days starting from the 1st day of EAE induction: anti-S100 (n = 20, 2.5 mL/ kg/d); distilled water (control; n = 20, 5 mL/kg/d). Reference drug (Glatiramer acetate, Copaxone®, Teva, Israel, n = 20) was administered intramuscularly (4 mg/kg) from the 2nd to the 25th day after EAE induction.
PP261-UTilizaTion of TriPTanes in sweden; analyses of over The coUnTer and PrescriPTions sales
Barcelona Health Region, Catalan Health Service, Barcelona, Spain Introduction: There could be an opportunity for health authorities to take advantage of oral generic atypical antipsychotic drugs (AAPs) given their considerable expenditure across countries. However, schizophrenia and bipolar disorders (BPD) are complex to treat, with the need to tailor treatments. Consequently, there is a need to assess changes in risperidone utilization before and after oral generic risperidone was reimbursed among European countries, as well as the utilization of generic versus originator risperidone, to provide future guidance. Patients (or Materials) and Methods: We principally used an interrupted time series design of monthly aggregated AAP utilization (2011 DDDs) up to 2 years before generic risperidone became available and reimbursed and up to 6 years after in Austria, Belgium, Ireland (GMS population), Scotland, Spain (Catalonia), and Sweden; (ii) Demand-side measures captured and categorised using the 4Es (Education, Engineering, Economics and Enforcement). Expenditure was also measured. Only administrative databases were used. Results: There were generally no specific measures among the various authorities to preferentially encourage the prescribing of oral Results: On admission, toxic plasma level of venlafaxine was found (2638 ng/mL) and after reduction of the dose to 75 mg/d plasma level was estimated in therapeutic range (364 ng/mL). The ratio O-desmethylvenlafaxine/venlafaxine was estimated between 0.005 and 0.016 showing poor metabolizator. Genetic examination detected homozygotes deletion of the gene CYP2D6 *5/*5 and explained phenotype. Plasma level of olanazapine was found in therapeutic range, plasma level of clonazepam was found below therapeutic range.
Conclusion:
The ratio of the metabolite to the parent substance (phenotype) allows us to detect any deviation in the metabolism of drugs which can be subsequently explained by determination of genotype. Therapeutic drug monitoring contributes to the optimalization of pharmacotherapy in the case of psychotropic drugs. Disclosure of Interest: None declared. Alzheimer's disease is a neurodegenerative disorder associated with depletion of acetylcholine in neuronal terminals with increased oxidative stress in cells resulting in neuroinflammation. Inhibiting acetylcholine esterase (AchE) increases the concentration of neuronal acetylcholine. Further xanthine oxidase (XO) is an important source of free radicals and plays an important role in oxidative stress associated with neuroinflammation. Thus, a dual acting inhibitor of AchE & XO can be a good candidate for the treatment of neurodegenerative disorders like Alzheimer's. The aim of this study is to explore the inhibitory potential of 4-methyl esculetin against both AchE and XO. Patients (or Materials) and Methods: The X-ray crystal structures of rivastigmine bound to acetylcholinesterase (AChE) (PDB 1GQR) and quercetin bound to xanthine oxidase (XO) (PBD 3NVY) were obtained from the Protein Data Bank. The proteins were prepared for the docking studies with the Protein Preparation Wizard in the Schrödinger Suite 2012 (Schrödinger LLC, USA). The ligand 4-methyl esculetin (4-ME) was docked into the target proteins AhcE and XO and binding poses ranked by Glide Score (SP). The inhibitory activity of 4-ME towards AchE was measured by an in vitro assay using rat brain AchE, and inhibition of XO was done using crude XO obtained from rat liver tissue. Results: The docking studies revealed that 4-methyl esculetin binds in a similar fashion to both AChE and XO and makes identical interactions as the native ligands (rivastigmine for AchE & quercetin for XO). The Glide Score for 4-methyl esculetin (-6.97 for AchE and -7.78 for XO) also does not differ significantly in both targets; hence, it can be said with confidence that 4-ME should exhibit comparable potency towards the 2 protein targets. This is well substantiated by in vitro enzyme assays that confirmed the equal inhibitory properties of 4-ME towards both the target viz. AchE and XO. Kinetic studies showed that 4-ME acts as a competitive inhibitor against XO while exhibiting mixed type inhibition toward AchE.
PP264-4-meThylescUleTin a dUal acTing inhibiTor of aceTylcholinesTerase and xanThine oxidase

Conclusion:
The results of the present study indicate that a combination of both AchE and XO inhibitory properties for 4-ME could make it a useful asset in the management of Alzheimer's disease. Disclosure of Interest: None declared.
PP265-aTTenUaTion of alUminiUm indUced neUrodegeneraTion by 4-meThylescUleTin
T. Shirole * ; D. Makhija; and A. Jagtap Pharmacology, Bombay College of Pharmacy, Mumbai, India Introduction: Aluminium is a potent neurotoxin and has been associated with Alzheimer's disease (AD). Prolonged aluminium exposure induces oxidative stress and contributes to the development of neurodegeneration. Current treatment modalities for AD provide only symptomatic relief, thus necessitating the development of new drugs with multiple targeting strategies. The aim of the study was to demonstrate the protective effect of chronic administration of 4-methylesculetin (4-ME) against aluminium-induced cognitive dysfunction and oxidative damage in rats. Patients (or Materials) and Methods: Wistar rats (180-200 g) were divided into 6 groups (n = 6). Group I was the control group and group II received aluminium chloride (100 mg/kg PO) for a period of 42 days. Group III and IV received 4-ME (50 and 100 mg/kg PO) daily 1 hour before aluminium chloride (100 mg/kg PO) for 42 days while groups V and VI received only 4-ME (50 and 100 mg/kg PO) daily for 42 days. On the 21st and 42nd day, behavioral studies
